Print this page
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy: A Phase II Randomized Trial.
Primary:
To compare progression free survival between patients treated with SABR to all oligoprogressive lesions vs. those treated with standard of care (which can include switch to next line of systemic, observation or continue current systemic therapy without SABR).
Secondary:
To compare overall survival (OS) between patients treated with SABR to all oligoprogressive lesions with continuation of current systemic therapy vs. those treated with standard of care (which can include switch to next line of systemic, observation or continue current systemic therapy without SABR).
Protocol Number:
152501
Phase:
Phase II
Applicable Disease Sites:
Any Site
Drugs Involved:
Vitamin C
Principal Investigator:
Lara Hathout
Scope:
National
Therapies Involved:
Radiotherapy
Participating Institutions:
- Rutgers University
For further information about clinical trials, please contact us at 732-235-7356.